NASDAQ : ABOS
Acumen Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.2101 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 15.20M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 17.34M |
| Enterprise Value | -34.96M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 72.33M |
| Shares Outstanding | 72.33M |
| Shares Change (YoY) | +11.05% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 14.60% |
| Owned by Institutions (%) | 34.77% |
| Float | 37.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.89 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.65 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -162.72% |
| Return on Assets (ROA) | -57.46% |
| Return on Invested Capital (ROIC) | -70.78% |
| Return on Capital Employed (ROCE) | -258.70% |
| Weighted Average Cost of Capital (WACC) | 10.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -89.15% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 2.49 |
| Relative Strength Index (RSI) | 21.07 |
| Average Volume (20 Days) | 5,692,876 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.09M |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 4.27% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 5.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -85.93M |
| Operating Income | -104.72M |
| Pretax Income | -103.96M |
| Net Income | -103.96M |
| EBITDA | -104.67M |
| EBIT | -104.72M |
| Earnings Per Share (EPS) | -$1.55 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 78.60M |
| Total Debt | 26.31M |
| Net Cash | 52.29M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 34.61M |
| Book Value Per Share | 0.48 |
| Working Capital | 40.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -87.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 47,000 |
| Net Borrowing | -4.99M |
| Free Cash Flow | -87.95M |
| FCF Per Share | -$1.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.05% |
| Shareholder Yield | -11.05% |
| Earnings Yield | -646.22% |
| FCF Yield | -578.79% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.00 |
| Price Target Difference | 317.19% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |